$VRSK

Mann Elizabeth sold $72K of VRSK

Mann Elizabeth (Chief Financial Officer) sold 400 shares of Verisk Analytics, Inc. (VRSK) at $179.95 on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mann Elizabeth
Published Aug 17, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include any new company-specific operational, financial, or regulatory information.

02

Market read

Traders may note the CFO’s 10b5-1 sale, but it is generally treated as low-signal for fundamentals.

03

What to watch

The transaction size is small relative to typical institutional float, and the 10b5-1 designation suggests the sale timing was pre-set rather than information-driven.

Relevance 2/10Novelty 2/10Timing: filed 2026-08-17 (same day disclosure)

Background

This is an SEC Form 4 insider transaction disclosure for Verisk Analytics, Inc., reported by the CFO.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Verisk CFO Mann Elizabeth filed a Form 4 open-market sale of 400 shares at $179.95 on 2026-08-17 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades for 10b5-1 sales.

Evidence & confidence

The filing specifies an open-market sale executed under a pre-arranged Rule 10b5-1 plan, which generally reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single routine 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of valuation or liquidity needs, so some traders may still watch for follow-on selling patterns.

Key entities

  • Verisk Analytics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Mann Elizabeth

    Chief Financial Officer who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer